vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Limbach Holdings, Inc. (LMB). Click either name above to swap in a different company.
Limbach Holdings, Inc. is the larger business by last-quarter revenue ($186.9M vs $180.9M, roughly 1.0× AVANOS MEDICAL, INC.). Limbach Holdings, Inc. runs the higher net margin — 6.6% vs -0.7%, a 7.3% gap on every dollar of revenue. On growth, Limbach Holdings, Inc. posted the faster year-over-year revenue change (30.1% vs 0.7%). Limbach Holdings, Inc. produced more free cash flow last quarter ($27.9M vs $21.3M). Over the past eight quarters, Limbach Holdings, Inc.'s revenue compounded faster (25.3% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Limbach Flugmotoren is a Chinese-owned company based in Germany that produces aircraft engines.
AVNS vs LMB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $186.9M |
| Net Profit | $-1.3M | $12.3M |
| Gross Margin | 47.5% | 25.7% |
| Operating Margin | 1.4% | 9.4% |
| Net Margin | -0.7% | 6.6% |
| Revenue YoY | 0.7% | 30.1% |
| Net Profit YoY | 99.7% | 25.0% |
| EPS (diluted) | $-0.02 | $1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $186.9M | ||
| Q3 25 | $177.8M | $184.6M | ||
| Q2 25 | $175.0M | $142.2M | ||
| Q1 25 | $167.5M | $133.1M | ||
| Q4 24 | $179.6M | $143.7M | ||
| Q3 24 | $170.4M | $133.9M | ||
| Q2 24 | $171.7M | $122.2M | ||
| Q1 24 | $166.1M | $119.0M |
| Q4 25 | $-1.3M | $12.3M | ||
| Q3 25 | $-1.4M | $8.8M | ||
| Q2 25 | $-76.8M | $7.8M | ||
| Q1 25 | $6.6M | $10.2M | ||
| Q4 24 | $-397.3M | $9.8M | ||
| Q3 24 | $4.3M | $7.5M | ||
| Q2 24 | $1.8M | $6.0M | ||
| Q1 24 | $-900.0K | $7.6M |
| Q4 25 | 47.5% | 25.7% | ||
| Q3 25 | 48.4% | 24.2% | ||
| Q2 25 | 52.6% | 28.0% | ||
| Q1 25 | 53.6% | 27.6% | ||
| Q4 24 | 54.6% | 30.3% | ||
| Q3 24 | 54.5% | 27.0% | ||
| Q2 24 | 55.7% | 27.4% | ||
| Q1 24 | 57.1% | 26.1% |
| Q4 25 | 1.4% | 9.4% | ||
| Q3 25 | 0.1% | 7.2% | ||
| Q2 25 | -42.6% | 7.5% | ||
| Q1 25 | 6.1% | 5.9% | ||
| Q4 24 | -233.0% | 9.1% | ||
| Q3 24 | 7.0% | 8.1% | ||
| Q2 24 | 3.7% | 6.7% | ||
| Q1 24 | 2.4% | 5.5% |
| Q4 25 | -0.7% | 6.6% | ||
| Q3 25 | -0.8% | 4.8% | ||
| Q2 25 | -43.9% | 5.5% | ||
| Q1 25 | 3.9% | 7.7% | ||
| Q4 24 | -221.2% | 6.9% | ||
| Q3 24 | 2.5% | 5.6% | ||
| Q2 24 | 1.0% | 4.9% | ||
| Q1 24 | -0.5% | 6.4% |
| Q4 25 | $-0.02 | $1.01 | ||
| Q3 25 | $-0.03 | $0.73 | ||
| Q2 25 | $-1.66 | $0.64 | ||
| Q1 25 | $0.14 | $0.85 | ||
| Q4 24 | $-8.64 | $0.81 | ||
| Q3 24 | $0.09 | $0.62 | ||
| Q2 24 | $0.04 | $0.50 | ||
| Q1 24 | $-0.02 | $0.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $11.3M |
| Total DebtLower is stronger | $90.3M | $30.5M |
| Stockholders' EquityBook value | $778.2M | $195.7M |
| Total Assets | $1.1B | $381.1M |
| Debt / EquityLower = less leverage | 0.12× | 0.16× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $11.3M | ||
| Q3 25 | $70.5M | $9.8M | ||
| Q2 25 | $90.3M | $38.9M | ||
| Q1 25 | $97.0M | $38.1M | ||
| Q4 24 | $107.7M | $44.9M | ||
| Q3 24 | $89.0M | $51.2M | ||
| Q2 24 | $92.2M | $59.5M | ||
| Q1 24 | $75.8M | $48.2M |
| Q4 25 | $90.3M | $30.5M | ||
| Q3 25 | $93.4M | $56.3M | ||
| Q2 25 | $95.7M | $28.4M | ||
| Q1 25 | $98.0M | $23.7M | ||
| Q4 24 | $125.3M | $23.6M | ||
| Q3 24 | $152.6M | $20.5M | ||
| Q2 24 | $164.9M | $19.7M | ||
| Q1 24 | $167.2M | $19.4M |
| Q4 25 | $778.2M | $195.7M | ||
| Q3 25 | $778.0M | $181.6M | ||
| Q2 25 | $776.3M | $170.5M | ||
| Q1 25 | $839.4M | $161.1M | ||
| Q4 24 | $828.5M | $153.5M | ||
| Q3 24 | $1.2B | $142.2M | ||
| Q2 24 | $1.2B | $133.0M | ||
| Q1 24 | $1.2B | $125.5M |
| Q4 25 | $1.1B | $381.1M | ||
| Q3 25 | $1.1B | $409.1M | ||
| Q2 25 | $1.0B | $343.0M | ||
| Q1 25 | $1.1B | $336.4M | ||
| Q4 24 | $1.2B | $352.1M | ||
| Q3 24 | $1.7B | $324.4M | ||
| Q2 24 | $1.7B | $303.9M | ||
| Q1 24 | $1.7B | $289.2M |
| Q4 25 | 0.12× | 0.16× | ||
| Q3 25 | 0.12× | 0.31× | ||
| Q2 25 | 0.12× | 0.17× | ||
| Q1 25 | 0.12× | 0.15× | ||
| Q4 24 | 0.15× | 0.15× | ||
| Q3 24 | 0.12× | 0.14× | ||
| Q2 24 | 0.13× | 0.15× | ||
| Q1 24 | 0.14× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $28.1M |
| Free Cash FlowOCF − Capex | $21.3M | $27.9M |
| FCF MarginFCF / Revenue | 11.8% | 14.9% |
| Capex IntensityCapex / Revenue | 3.8% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 2.29× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $28.1M | ||
| Q3 25 | $14.0M | $13.3M | ||
| Q2 25 | $6.8M | $2.0M | ||
| Q1 25 | $25.7M | $2.2M | ||
| Q4 24 | $57.9M | $19.3M | ||
| Q3 24 | $23.0M | $4.9M | ||
| Q2 24 | $27.8M | $16.5M | ||
| Q1 24 | $-8.0M | $-3.9M |
| Q4 25 | $21.3M | $27.9M | ||
| Q3 25 | $7.0M | $12.8M | ||
| Q2 25 | $-4.2M | $1.2M | ||
| Q1 25 | $19.0M | $11.0K | ||
| Q4 24 | $53.1M | $18.0M | ||
| Q3 24 | $20.0M | $4.6M | ||
| Q2 24 | $21.9M | $13.2M | ||
| Q1 24 | $-12.1M | $-6.5M |
| Q4 25 | 11.8% | 14.9% | ||
| Q3 25 | 3.9% | 7.0% | ||
| Q2 25 | -2.4% | 0.8% | ||
| Q1 25 | 11.3% | 0.0% | ||
| Q4 24 | 29.6% | 12.5% | ||
| Q3 24 | 11.7% | 3.4% | ||
| Q2 24 | 12.8% | 10.8% | ||
| Q1 24 | -7.3% | -5.5% |
| Q4 25 | 3.8% | 0.1% | ||
| Q3 25 | 3.9% | 0.3% | ||
| Q2 25 | 6.3% | 0.6% | ||
| Q1 25 | 4.0% | 1.7% | ||
| Q4 24 | 2.7% | 0.9% | ||
| Q3 24 | 1.8% | 0.3% | ||
| Q2 24 | 3.4% | 2.7% | ||
| Q1 24 | 2.5% | 2.1% |
| Q4 25 | — | 2.29× | ||
| Q3 25 | — | 1.52× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | 3.89× | 0.22× | ||
| Q4 24 | — | 1.96× | ||
| Q3 24 | 5.35× | 0.66× | ||
| Q2 24 | 15.44× | 2.77× | ||
| Q1 24 | — | -0.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
LMB
| Owner Direct Relationships Segment | $145.0M | 78% |
| General Contractor Construction Manager Relationships Segment | $41.9M | 22% |
